Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines

Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue to need treatment within 6 months before the RSV season. The utilization patterns of treatment (chronic corticosteroid therapy, diuretic ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yoonyoung, Meissner, H. Cody, Hampp, Christian, Park, Haesuk, Winterstein, Almut G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349231/
https://www.ncbi.nlm.nih.gov/pubmed/34365543
http://dx.doi.org/10.1007/s00431-021-04233-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349231/
https://www.ncbi.nlm.nih.gov/pubmed/34365543
http://dx.doi.org/10.1007/s00431-021-04233-6

Ejemplares similares